Llama Antibody Inhibits Botulinum Neruotoxin
From Proteopedia
| Line 1: | Line 1: | ||
| - | '''PubMed Abstract:''' | + | '''[http://www.rcsb.org/pdb/explore/explore.do?structureId=3K3Q PubMed Abstract]:''' |
{{STRUCTURE_3k3q| PDB=3k3q | SCENE= }} | {{STRUCTURE_3k3q| PDB=3k3q | SCENE= }} | ||
Ingestion or inhalation of botulinum neurotoxin (BoNT) results in botulism, a severe and frequently fatal disease. Current treatments rely on antitoxins, which, while effective, cannot reverse symptoms once BoNT has entered the neuron. For treatments that can reverse intoxication, interest... [ Read More & Search PubMed Abstracts ] | Ingestion or inhalation of botulinum neurotoxin (BoNT) results in botulism, a severe and frequently fatal disease. Current treatments rely on antitoxins, which, while effective, cannot reverse symptoms once BoNT has entered the neuron. For treatments that can reverse intoxication, interest... [ Read More & Search PubMed Abstracts ] | ||
Revision as of 22:34, 16 November 2010
PubMed Abstract: Template:STRUCTURE 3k3q Ingestion or inhalation of botulinum neurotoxin (BoNT) results in botulism, a severe and frequently fatal disease. Current treatments rely on antitoxins, which, while effective, cannot reverse symptoms once BoNT has entered the neuron. For treatments that can reverse intoxication, interest... [ Read More & Search PubMed Abstracts ] Ingestion or inhalation of botulinum neurotoxin (BoNT) results in botulism, a severe and frequently fatal disease. Current treatments rely on antitoxins, which, while effective, cannot reverse symptoms once BoNT has entered the neuron. For treatments that can reverse intoxication, interest has focused on developing inhibitors of the enzymatic BoNT light chain (BoNT Lc). Such inhibitors typically mimic substrate and bind in or around the substrate cleavage pocket. To explore the full range of binding sites for serotype A light chain (BoNT/A Lc) inhibitors, we created a library of non-immune llama single-domain VHH (camelid heavy-chain variable region derived from heavy-chain-only antibody) antibodies displayed on the surface of the yeast Saccharomyces cerevisiae. Library selection on BoNT/A Lc yielded 15 yeast-displayed VHH with equilibrium dissociation constants (K(d)) from 230 to 0.03 nM measured by flow cytometry. Eight of 15 VHH inhibited the cleavage of substrate SNAP25 (synaptosome-associated protein of 25,000 Da) by BoNT/A Lc. The most potent VHH (Aa1) had a solution K(d) for BoNT/A Lc of 1.47 x 10(-)(10) M and an IC(50) (50% inhibitory concentration) of 4.7 x 10(-)(10) M and was resistant to heat denaturation and reducing conditions. To understand the mechanism by which Aa1 inhibited catalysis, we solved the X-ray crystal structure of the BoNT/A Lc-Aa1 VHH complex at 2.6 A resolution. The structure reveals that the Aa1 VHH binds in the alpha-exosite of the BoNT/A Lc, far from the active site for catalysis. The study validates the utility of non-immune llama VHH libraries as a source of enzyme inhibitors and identifies the BoNT/A Lc alpha-exosite as a target for inhibitor development.
Clostridium Botulinum
C. Botulinum is a Gram Positive bacteria belonging to the group of Firmicutes. They are obligate anaerobes capable of producing endospores. C. Botulinum is capable of producing a neurotoxin that causes muscle paralysis. The toxin can enter the body in many different ways: colonization of the digestive tract in both adults (Adult intestinal toxemia) and infants (infant botulism), ingestion of toxin from foods (Foodborne Botulism), and entry of a wound (Wound botulism).
